Your browser doesn't support javascript.
loading
Integrative medicine use in patients with cutaneous T-Cell lymphoma: A cross-sectional survey study.
Mahurin, Heather M; Tarabadkar, Erica; Hippe, Daniel S; Lachance, Kristina; Kim, Ellen J; Loggers, Elizabeth T; Shinohara, Michi M.
Afiliação
  • Mahurin HM; University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, United States. Electronic address: mahurinh@uw.edu.
  • Tarabadkar E; Department of Dermatology, Emory University, 1525 Clifton Rd, Atlanta, GA, 30322, United States.
  • Hippe DS; Department of Radiology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, United States.
  • Lachance K; Division of Dermatology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, United States.
  • Kim EJ; Department of Dermatology, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, United States.
  • Loggers ET; Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA, 98109, United States; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, United States.
  • Shinohara MM; Division of Dermatology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, United States.
Complement Ther Med ; 61: 102762, 2021 Sep.
Article em En | MEDLINE | ID: mdl-34302983
ABSTRACT

OBJECTIVES:

To characterize patterns of integrative medicine (IM) use and health-related quality of life (HRQoL) in patients with cutaneous T-cell lymphoma (CTCL).

DESIGN:

Cross-sectional, online survey, created in conjunction with the Cutaneous Lymphoma Foundation (CLF).

SETTING:

A link to the online survey was posted on the CLF Facebook page and emailed to the CLF listserv; 372 survey responses were received. MAIN OUTCOME

MEASURES:

The study outcomes were IM use, cancer symptoms, and HRQoL measured via the Skindex-16 and Functional Assessment of Cancer Therapy-General (FACT-G).

RESULTS:

A total of 292 patient responses (66 % female, median age 59y) were included in analysis. 87 % had mycosis fungoides and 12 % had Sézary syndrome. A majority (59 %) of patients reported using IM for their CTCL, with 48 % using IM to treat their disease and 47 % using IM to manage their symptoms. The most commonly used IM were vitamins/minerals (32 %), prayer/meditation (26 %), diet (24 %), and exercise/yoga (22 %). Higher itch scores were reported by patients using IM compared to non-users (31 (IQR 10-62) and 18 (IQR 3-46) respectively; p = 0.002). HRQoL was worse among patients who reported IM use; median Skindex-16 scores were 54 (IQR 28-72) among IM users compared to 33 (IQR 19-57) for non-IM users (p < 0.001).

CONCLUSIONS:

IM use is common among patients with CTCL, particularly those with worse itching and worse HRQoL. IM interventions require further study given use by CTCL patients to treat disease and ameliorate symptoms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Linfoma Cutâneo de Células T / Medicina Integrativa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Linfoma Cutâneo de Células T / Medicina Integrativa Idioma: En Ano de publicação: 2021 Tipo de documento: Article